OpenAI has introduced MedChemBench, a benchmark designed to test whether AI models can work through selected reasoning tasks in medicinal chemistry. The announcement is important because it moves beyond generic science questions and evaluates tasks that resemble decisions researchers make while studying candidate compounds.
But the benchmark needs to be read carefully. A high score on a research benchmark is not the same as discovering a new medicine, proving that a drug is safe or replacing experiments in a laboratory.
What MedChemBench measures
OpenAI says MedChemBench contains 99 problems drawn from 117 published papers and patents. The tasks cover 761 distinct molecular structures. Models are given research context such as a biological target, the goals of a research programme, compounds already studied and selected experimental findings.
The benchmark evaluates four broad abilities: reconstructing molecular structures from supplied information, explaining experimental evidence, selecting compounds for further investigation and predicting numerical properties.
These are connected tasks. A medicinal chemist may need to understand why a small change in a molecule improves one property but makes another worse. A compound may interact strongly with a target but be poorly absorbed or break down too quickly. The challenge is to reason across several competing properties rather than optimise one number in isolation.
The headline score and the important distinction
At the xhigh reasoning setting, OpenAI reports that GPT-6.2 Astra earned 84.5% of the available credit. The same announcement reports 83.3% for GPT-6 Astra, 82.0% for GPT-6.1 Sol and 58.2% for GPT-5.6 Sol.
The distinction between GPT-6.2 Astra and GPT-6 Astra matters. They are different model versions, and the score should not be attributed to the wrong one.
OpenAI also says the models performed differently across the benchmark’s component tasks. Reconstructing structures and explaining evidence were stronger areas for some models, while selecting compounds and predicting numerical properties remained harder.
That variation is more useful than a single leaderboard number. In scientific work, a system can be impressive at explaining a known result and still be unreliable when asked to recommend the next experiment.
Why a benchmark like this matters
Drug research involves large amounts of specialised information. Scientists must connect molecular structure, experimental results, biological mechanisms and trade-offs. A model that can organise and reason over this information may help researchers explore evidence faster.
A benchmark provides a repeatable way to test some of those capabilities. It also makes weaknesses visible. If a model struggles to select the next compound or predict a measurement, a research team can focus its review on those tasks instead of assuming the model is equally capable everywhere.
What the score does not prove
MedChemBench does not establish that GPT-6.2 Astra can independently discover new drugs. It does not prove that a suggested compound will work in a living organism, pass safety testing or succeed in a clinical trial.
The benchmark is based on problems drawn from existing research material. It tests performance on those tasks under a defined evaluation setup. Real drug development also requires laboratory synthesis, biological testing, toxicology, clinical studies, regulatory review and many years of evidence.
A model’s answer must therefore be treated as a research aid that scientists can inspect, challenge and verify.
How Indian research teams could use this kind of benchmark
Universities, pharmaceutical companies and contract research organisations in India could use similar evaluations to decide where AI assistance is worth testing. A useful pilot would compare model outputs with expert-reviewed answers on a narrow task, such as extracting evidence from papers or explaining structure-property relationships.
The evaluation should record correct answers, unsupported claims, missed caveats, reproducibility and the time experts spend checking outputs. It should also keep confidential research data away from systems that are not approved to process it.
The practical takeaway
The value of MedChemBench is not that it declares AI ready to invent medicines. Its value is that it creates a more specific test of where models can help and where human scientific judgement remains essential.
For science, a benchmark score should be the beginning of a careful evaluation, not the end of one.
Source and reporting note: This article reports the benchmark and results described by OpenAI. We were not involved in the research, benchmark construction or model evaluation. For the full methodology, limitations and paper, consult the original OpenAI announcement and linked research paper.